India is expected to rein in the ‘unfettered’ run of e-pharmacies, a segment where top Indian conglomerates and Amazon have made strides, with pharma intertwined having tapped into these platforms. Scrip speaks to experts on areas of concern including prescription ‘workarounds’, supply chain transparency and data privacy where more oversight is called for amid the evolving regulatory landscape.

Wider-ranging new draft rules suggest that physicians in India should not engage in educational activity sponsored by pharma and urges them to declare financial earnings and benefits received from industry via an affidavit. The Pink Sheet discusses with industry experts some of the nuances and seeming loopholes in the rules, currently in self-regulatory mode but with penalties proposed for violation.

Biopharma and legal experts discussed at a recent summit the need for multi-stakeholder action to foster trust across the healthcare system. Capital is going to flow away from unethical organizations, one executive predicted.